No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IVA Inventiva
- 3.450
- +0.020+0.58%
Close May 7 16:00 ET
- 3.480
- +0.030+0.87%
Post 17:54 ET
179.80MMarket Cap-1319P/E (TTM)
3.550High3.380Low22.27KVolume3.550Open3.430Pre Close77.60KTurnover0.16%Turnover RatioLossP/E (Static)52.12MShares5.05052wk High-5.22P/B48.85MFloat Cap2.45852wk Low--Dividend TTM14.16MShs Float19.064Historical High--Div YieldTTM4.96%Amplitude2.220Historical Low3.484Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Inventiva Is Maintained at Buy by Canaccord Genuity
Inventiva Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the Inventiva (IVA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $12.00 to $20.00.
Canadian Investment Banking Group: Maintaining the Inventiva (IVA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $12.00 to $20.00.
Canaccord Genuity Maintains Buy on Inventiva, Raises Price Target to $20
Canaccord Genuity analyst Edward Nash maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $12 to $20.
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg